Anti-tumor drugs became the hottest treatments in December
Danni Yin · 01/19/2022
The NMPA’s run of speedy approvals continued in the last month of 2021 as Chinese regulators granted the first marketing approvals to 16 new drugs and accepted NDAs for 11 more new ones.
READ MORE
China introduces new pediatric drug regulations
Minhua Chu · 09/30/2021
Chinese drug regulators are making it clear that pediatric drug development is at the top of its agenda with a slew of new regulations.
READ MORE
Innovent's NDA for PD-1 drug as first-line treatment for ESCC accepted in China
Elise Mak · 09/23/2021
China's NMPA has accepted the supplemental NDA for Innovent's PD-1 drug sintilimab in combination with chemotherapy as the first-line treatment of esophageal squamous cell carcinoma.
READ MORE
China Unveils its First Drug Patent Linkage System
Minhua Chu · 08/25/2021
Both events marks the official implementation of China's drug patent linkage system.
READ MORE
ADCs are on the Rise in China
Danni Yin · 08/06/2021
Three ADCs have been approved by NMPA.
READ MORE
China Market Approvals Surge in June
Minhua Chu · 07/23/2021
China Market Approval Tracker: Jun 2021
READ MORE
Do NMPA Approvals Cause Share Prices to Rise?
Shi Yingzi · 07/29/2021
three fourths of stocks to rise on the day of approval.
READ MORE
China Approved its First Cell Therapy
Shi Yingzi · 07/19/2021
On June 22, NMPA green-lighted Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B cell lymphoma.
READ MORE
NMPA Re-elected as ICH Management Committee Member, Driving Innovations in China's Drug Regulations
Minhua Chu · 07/19/2021
"The NMPA stands in the international arena with clear goals and intentions and will actively participate in the ICH’s international affairs in the future."
READ MORE
READ MORE
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement